(MoneyNewsWire.Net, October 11, 2017 ) North America Alzheimer’s Disease Therapeutics and Diagnostics Market, published by Market Data Forecast the Market was worth USD 3.07 billion in 2016 and estimated to be growing at a CAGR of 4.55%, to reach USD 3.84 billion by 2021. Alzheimer’s disease is a neurodegenerative, progressive, non-reversible ailment that is caused due to irregular functioning of brain cells i.e. breakdown of synaptic communication, ensuing in the loss of cerebral functions.
Certain signs and indications of Alzheimer’s disease are memory loss, sleeplessness, recurring movements, anxiety, despair and loss of reasoning capabilities. All memory and cerebral functioning may be lost in the advanced stages of the disease. According to the International Institute of Aging, Alzheimer’s disease is the most frequent form of dementia.
Get a comprehensive overview of the North America Alzheimer’s Disease Therapeutics and Diagnostics Market: http://www.marketdataforecast.com/market-reports/north-america-alzheimers-disease-therapeutics-and-diagnostics-market-2248/
The growth of the North America Alzheimer’s disease Therapeutics and Diagnostics Market is mainly driven by factors such as rising geriatric populace, upsurge in healthcare spending and increasing government subsidy. In addition, growing healthcare cognizance and innovative diagnostic technologies are also stimulating the growth of the market. However, several factors such as stringent regulations, long authorization time for new medicines, and expiration of numerous patent drugs are restraining the growth of the Alzheimer’s disease Therapeutics and Diagnostics market in this region.
Get accurate market forecast and analysis on the North America Blood Pressure Monitoring Devices Market. Request a sample to stay up-to-date on the main trends affecting this market: http://www.marketdataforecast.com/market-reports/north-america-alzheimers-disease-therapeutics-and-diagnostics-market-2248/request-sample
The North America Alzheimer’s Disease Therapeutics and Diagnostics market is segmented based on Therapeutics and Diagnostics. The market for Alzheimer’s disease Therapeutics and Diagnostics, on the basis of Therapeutics is segmented into Marketed Drugs and Pipeline Drugs. Marketed Drugs are further segmented into NMDA Receptor Antagonists and Cholinesterase Inhibitors. Marketed Drugs lead the market on the basis of Therapeutics due to a large user base. On the basis of Diagnostics, the Alzheimer’s disease Therapeutics and Diagnostics market is segmented into Computed tomography scan, Electroencephalography, Lumbar puncture test, Magnetic resonance imaging, Positron emission tomography, and Others. Under this segment, Computed tomography scan segment leads the Alzheimer’s disease Therapeutics and Diagnostics market. Absence of alternative imaging tool for brain and neurological diagnostics is one of the crucial reasons for its large share.
The North America market has been geographically segmented into segmented into US and Canada. According to Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer's disease. One in nine people aged 65 and above has Alzheimer's disease. By 2050, the number of people aged 65 and above affected with Alzheimer's disease is projected to nearly triple, from 5.2 million to an expected 13.8 million. Increasing R&D activity and a strong pipeline of disease modifying drugs are the crucial factors driving the growth of the market in this region.
Leading companies have applied tactics such as mergers & acquisitions, collaborations, and joint ventures to gain a strong foothold in the market. The major companies dominating the Alzheimer’s Disease Therapeutics and Diagnostics market in this region are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare, Janssen Pharmaceuticals etc.
About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com.
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com
|